» Articles » PMID: 31436873

Biology and Significance of Alpha-fetoprotein in Hepatocellular Carcinoma

Overview
Journal Liver Int
Specialty Gastroenterology
Date 2019 Aug 23
PMID 31436873
Citations 255
Authors
Affiliations
Soon will be listed here.
Abstract

Hepatocellular carcinoma (HCC) is one of the most common causes of cancer-related deaths globally due, in part, to the majority of patients being diagnosed with intermediate or advanced stage disease. Our increased understanding of the heterogeneous molecular pathogenesis of HCC has led to significant developments in novel targeted therapies. Despite these advances, there remains a high unmet need for new treatment options. HCC is a complex disease with multiple pathogenic mechanisms caused by a variety of risk factors, making it difficult to characterize with a single biomarker. In fact, numerous biomarkers have been studied in HCC, but alpha-fetoprotein (AFP) remains the most widely used and accepted serum marker since its discovery over 60 years ago. This review summarizes the most relevant studies associated with the regulation of AFP at the gene and protein levels; the pathophysiology of AFP as a pro-proliferative protein; and the correlation of AFP with molecular HCC subclasses, the vascular endothelial growth factor pathway and angiogenesis. Also described are the historical and current uses of AFP for screening and surveillance, diagnosis, its utility as a prognostic and predictive biomarker and its role as a tumour antigen in HCC. Taken together, these data demonstrate the relevance of AFP for patients with HCC and identify several remaining questions that will benefit from future research.

Citing Articles

CNPY2 in Solid Tumors: Mechanisms, Biomarker Potential, and Therapeutic Implications.

Chowdhury S, Hong F, Rolfo C, Li Z, He K, Wesolowski R Biology (Basel). 2025; 14(2).

PMID: 40001982 PMC: 11851889. DOI: 10.3390/biology14020214.


CRAFITY score and nomogram predict the clinical efficacy of lenvatinib combined with immune checkpoint inhibitors in hepatocellular carcinoma.

Yin X, Deng N, Ding X, Chen J, Sun W World J Gastroenterol. 2025; 31(7):101672.

PMID: 39991685 PMC: 11755258. DOI: 10.3748/wjg.v31.i7.101672.


Imaging-Based Prediction of Ki-67 Expression in Hepatocellular Carcinoma: A Retrospective Study.

Cai C, Wang L, Tao L, Zhu H, Ren Y, Li D Cancer Med. 2025; 14(4):e70562.

PMID: 39964132 PMC: 11834164. DOI: 10.1002/cam4.70562.


Radiological and clinical signatures to differentiate hepatocellular carcinoma from hepatoblastoma in children older than 5 years of age: a feasibility study.

Ozer G, Ozcan H, Ardicli B, Kutluk T, Oguz B, Haliloglu M Pediatr Radiol. 2025; .

PMID: 39961817 DOI: 10.1007/s00247-025-06190-w.


Effect of combining serum alpha-fetoprotein with LI-RADS v2018 on gadoxetate-enhanced MRI in the diagnosis and prognostication of hepatocellular carcinoma.

Kim D, Choi S, Koo B, Choi S, Jang H, Heo S Eur Radiol. 2025; .

PMID: 39930127 DOI: 10.1007/s00330-025-11418-2.